TrialRheumatology (Oxford, England)2020

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.

Eric F Morand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.